JPWO2020227474A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020227474A5 JPWO2020227474A5 JP2021566152A JP2021566152A JPWO2020227474A5 JP WO2020227474 A5 JPWO2020227474 A5 JP WO2020227474A5 JP 2021566152 A JP2021566152 A JP 2021566152A JP 2021566152 A JP2021566152 A JP 2021566152A JP WO2020227474 A5 JPWO2020227474 A5 JP WO2020227474A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- polypeptide
- domain
- item
- natural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845304P | 2019-05-08 | 2019-05-08 | |
| US62/845,304 | 2019-05-08 | ||
| US201962898392P | 2019-09-10 | 2019-09-10 | |
| US62/898,392 | 2019-09-10 | ||
| PCT/US2020/031780 WO2020227474A1 (en) | 2019-05-08 | 2020-05-07 | Cd33 targeted immunotherapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531719A JP2022531719A (ja) | 2022-07-08 |
| JPWO2020227474A5 true JPWO2020227474A5 (enExample) | 2023-06-23 |
| JP7765291B2 JP7765291B2 (ja) | 2025-11-06 |
Family
ID=73050903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566152A Active JP7765291B2 (ja) | 2019-05-08 | 2020-05-07 | Ｃｄ３３標的免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220324942A1 (enExample) |
| EP (1) | EP3966251A4 (enExample) |
| JP (1) | JP7765291B2 (enExample) |
| KR (1) | KR20220031554A (enExample) |
| CN (1) | CN114206928B (enExample) |
| AU (1) | AU2020268379A1 (enExample) |
| BR (1) | BR112021022356A2 (enExample) |
| CA (1) | CA3139096A1 (enExample) |
| IL (1) | IL287770A (enExample) |
| MA (1) | MA55907A (enExample) |
| MX (1) | MX2021013591A (enExample) |
| SG (1) | SG11202111890RA (enExample) |
| WO (1) | WO2020227474A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2022171113A1 (zh) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | 人cd33抗体及其用途 |
| CA3240542A1 (en) * | 2021-12-10 | 2023-06-15 | Jacob S. APPELBAUM | Methods and compositions for modulating the activity of a dimerizing agent regulated immunomodulatory complex |
| IL316032A (en) * | 2022-04-08 | 2024-11-01 | Regeneron Pharma | Multicomponent receptor and signaling complexes |
| EP4511394A2 (en) * | 2022-04-22 | 2025-02-26 | Inhibrx Biosciences, Inc. | Siglec-8 binding proteins and uses thereof |
| CN119585438A (zh) | 2022-05-26 | 2025-03-07 | 再生元制药公司 | 用于维持慢病毒载体的组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| CA2956667A1 (en) * | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| JP6673848B2 (ja) * | 2014-04-03 | 2020-03-25 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｃｄ３３特異的キメラ抗原受容体 |
| ES2846811T3 (es) * | 2014-06-06 | 2021-07-29 | Bluebird Bio Inc | Composiciones de células T mejoradas |
| EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
| KR20180042361A (ko) * | 2015-08-24 | 2018-04-25 | 셀렉티스 | 통합된 통제가능한 기능들을 가진 키메라 항원 수용체들 |
| WO2017100403A1 (en) * | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
| SG10201912405TA (en) * | 2016-01-11 | 2020-02-27 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
| WO2017156479A1 (en) * | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| US20190241910A1 (en) * | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| CN109311963A (zh) * | 2016-04-14 | 2019-02-05 | 蓝鸟生物公司 | 救助嵌合抗原受体系统 |
| EP3601356A1 (en) * | 2017-03-24 | 2020-02-05 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| EP3966245A1 (en) * | 2019-05-04 | 2022-03-16 | Inhibrx, Inc. | Cd33-binding polypeptides and uses thereof |
-
2020
- 2020-05-07 SG SG11202111890RA patent/SG11202111890RA/en unknown
- 2020-05-07 JP JP2021566152A patent/JP7765291B2/ja active Active
- 2020-05-07 KR KR1020217040150A patent/KR20220031554A/ko active Pending
- 2020-05-07 MA MA055907A patent/MA55907A/fr unknown
- 2020-05-07 MX MX2021013591A patent/MX2021013591A/es unknown
- 2020-05-07 AU AU2020268379A patent/AU2020268379A1/en active Pending
- 2020-05-07 EP EP20802310.1A patent/EP3966251A4/en active Pending
- 2020-05-07 US US17/608,743 patent/US20220324942A1/en active Pending
- 2020-05-07 BR BR112021022356A patent/BR112021022356A2/pt unknown
- 2020-05-07 CN CN202080048661.5A patent/CN114206928B/zh active Active
- 2020-05-07 CA CA3139096A patent/CA3139096A1/en active Pending
- 2020-05-07 WO PCT/US2020/031780 patent/WO2020227474A1/en not_active Ceased
-
2021
- 2021-11-01 IL IL287770A patent/IL287770A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016228080B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| CN113784732B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| JP2019518425A5 (enExample) | ||
| JP7767502B2 (ja) | Ｎｋ阻害性分子を発現する遺伝子改変免疫細胞とその使用 | |
| KR20230095083A (ko) | Cd7 표적의 키메라 항원 수용체 및 이의 용도 | |
| US20180223255A1 (en) | Activation and Expansion of T Cells | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| KR20160003071A (ko) | Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포 | |
| WO2015179801A1 (en) | Car based immunotherapy | |
| CN110157738B (zh) | 靶向cd19和cd22的工程化免疫细胞及其应用 | |
| WO2019223226A1 (zh) | 改良型抗cd19 car-t细胞 | |
| US11008556B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| JPWO2020227474A5 (enExample) | ||
| JP2017081836A (ja) | 細胞傷害性ｔ細胞の作製方法 | |
| AU2022202263A1 (en) | Composition and method for adoptive immunotherapy | |
| JPWO2020227475A5 (enExample) | ||
| JPWO2019241685A5 (enExample) | ||
| WO2022036224A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| JPWO2020123938A5 (enExample) | ||
| CN116462770A (zh) | Cd19的人源化抗体和一种表达双特异性嵌合抗原受体的car-t细胞及其应用 | |
| KR20240070523A (ko) | 키메라 항원 수용체 암 면역요법 효능을 증강시키기 위한 Bcl-2의 조절 | |
| Al-Khami et al. | Adoptive immunotherapy of cancer: Gene transfer of T cell specificity | |
| WO2023131063A1 (zh) | 特异性结合msln的嵌合抗原受体及其应用 | |
| HK40062446B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| HK1228783B (en) | Reducing immune tolerance induced by pd l1 |